Novartis Expects Thin Strips Technology To Drive OTC Cough/Cold Sales
This article was originally published in The Tan Sheet
Novartis Consumer Health is gearing up to launch new cough/cold products using a Thin Strips dosage form this summer
You may also be interested in...
Several OTC manufacturers are focusing on the adolescent and children's markets with product launches planned for the 2006-2007 cough/cold season
Novartis and Adhesive Research's ARx division are expanding their work on developing Thin Strip offerings and have broken ground on a new facility that will be used to manufacture products employing the technology, the firms announce May 19. ARx Division already supports six thin film products, including Triaminic Thin Strips and Theraflu Thin Strips, both introduced by Novartis (1"The Tan Sheet" April 26, 2004, p. 13). ARx is the exclusive developer and supplier of active films for Novartis, and plans to launch 20 new products over the next three years. The firm is also developing a 25,000 square-foot facility, to be located on the ARx campus in Glen Rock, Penn. Novartis' launch of its thin strip products is "just the beginning of a relationship that will benefit from this new state-of-the-art facility"...
Leiner will launch at least three new OTC drug and dietary supplement products in orally dissolving strip formulations later this year under a licensing agreement with MonoSol Rx